These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 18232197)

  • 1. [New drugs; daptomycin].
    van Bronswijk H; Dubois EA; van Dissel JT; Cohen AF
    Ned Tijdschr Geneeskd; 2007 Dec; 151(50):2777-8. PubMed ID: 18232197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria.
    Rybak MJ
    Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():24-32. PubMed ID: 16445721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daptomycin: first in a new class of antibiotics for complicated skin and soft-tissue infections.
    Kern WV
    Int J Clin Pract; 2006 Mar; 60(3):370-8. PubMed ID: 16494659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Daptomycin: revitalizing a former drug due to the need of new active agents against grampositive multiresistant bacterias].
    Hernández Martí V; Romá Sánchez E; Salavert Lletí M; Bosó Ribelles V; Poveda Andrés JL
    Rev Esp Quimioter; 2007 Sep; 20(3):261-76. PubMed ID: 18080024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Daptomycin--a new antibiotic for the treatment of skin and soft tissue infections].
    Mathiesen L; Midtvedt T; Solberg CO
    Tidsskr Nor Laegeforen; 2006 Sep; 126(18):2383-4. PubMed ID: 16998552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daptomycin.
    Enoch DA; Bygott JM; Daly ML; Karas JA
    J Infect; 2007 Sep; 55(3):205-13. PubMed ID: 17629567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of staphylococcal infections with cyclic lipopeptides.
    Eisenstein BI
    Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():10-6. PubMed ID: 18226085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria.
    Johnson A
    Future Microbiol; 2006 Oct; 1(3):255-65. PubMed ID: 17661638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of daptomycin in the empirical and directed therapy of infections caused by Gram-positive bacteria in the critically ill patient].
    Garnacho-Montero J; Amaya-Villar R; Gómez-Grande ML; Jerez V; Lorente-Ramos L; Loza A; Martínez A; Pozo JC; Sierra R; Pomares J; de la Torre MV; Ortiz C
    Rev Esp Quimioter; 2011 Mar; 24(1):13-24. PubMed ID: 21412665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD.
    Eisenstein BI; Oleson FB; Baltz RH
    Clin Infect Dis; 2010 Jan; 50 Suppl 1():S10-5. PubMed ID: 20067387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-clinical experience with daptomycin.
    Hawkey PM
    J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii7-14. PubMed ID: 18829726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Daptomycin: pharmacological characteristics and its role in the treatment of gram positive infections].
    Araos R; García P; Chanqueo L; Labarca J
    Rev Chilena Infectol; 2012 Apr; 29(2):127-31. PubMed ID: 22689024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daptomycin, a lipopeptide antibiotic in clinical practice.
    Weis F; Beiras-Fernandez A; Schelling G
    Curr Opin Investig Drugs; 2008 Aug; 9(8):879-84. PubMed ID: 18666036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.
    Steenbergen JN; Alder J; Thorne GM; Tally FP
    J Antimicrob Chemother; 2005 Mar; 55(3):283-8. PubMed ID: 15705644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections.
    Kanafani ZA; Corey GR
    Expert Rev Anti Infect Ther; 2007 Apr; 5(2):177-84. PubMed ID: 17402833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of cSSTIs: the role of daptomycin.
    Garau J
    Curr Med Res Opin; 2006 Nov; 22(11):2079-87. PubMed ID: 17076967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daptomycin.
    Prescrire Int; 2007 Dec; 16(92):245. PubMed ID: 18095389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.
    Arbeit RD; Maki D; Tally FP; Campanaro E; Eisenstein BI;
    Clin Infect Dis; 2004 Jun; 38(12):1673-81. PubMed ID: 15227611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes with daptomycin: a post-marketing, real-world evaluation.
    Sakoulas G
    Clin Microbiol Infect; 2009 Dec; 15 Suppl 6():11-6. PubMed ID: 19917022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Future directions with daptomycin.
    Livermore DM
    J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii41-iii49. PubMed ID: 18829725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.